Zai Lab is a biopharmaceutical company that focuses on developing innovative treatments for various medical conditions, including oncology, autoimmune disorders, infectious diseases, and neurological disorders. The company employs advanced technologies in its product pipeline, which includes a range of therapeutics designed to address unmet medical needs. Notable products include ZEJULA, a PARP inhibitor that targets DNA repair mechanisms in cancer cells, and OPTUNE, which utilizes Tumor Treating Fields (TTFields) technology to disrupt cancer cell division through electric fields. This innovative approach aims to enhance the efficacy of cancer treatments by directly targeting tumor cells while minimizing damage to surrounding healthy tissue.

In addition to these, Zai Lab's portfolio features several other advanced therapies, such as QINLOCK, a tyrosine kinase inhibitor that targets specific mutations in gastrointestinal stromal tumors (GIST), and AUGTYRO, which addresses ROS1-positive non-small cell lung cancer through next-generation kinase inhibition. The company also offers antibiotics like NUZYRA and XACDURO, which are designed to combat bacterial infections, and Efgartigimod, an antibody fragment that targets autoimmune diseases by modulating immune responses. Through these technologies, Zai Lab aims to leverage its research capabilities to improve patient outcomes and expand access to transformative medicines globally.

United States

Zai Lab is an innovative, research-based, commercial stage biopharmaceutical company based in China and the U.S. focused on bringing transformative medicines for cancer, autoimmune, and infectious diseases to patients in China and around the world. The company was founded by Dr. Samantha Du, Chairperson and CEO, in 2014 to help address significant unmet medical needs in China and to be at the forefront of medical innovation.

Zai Lab

Company Details